Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Seambiotic is an Israeli biotechnology company specializing in the cultivation of marine microalgae using recycled carbon dioxide from industrial flue gas. The company's proprietary technology platform integrates environmental protection with the production of high-value bio-products, including nutraceuticals like Omega-3 fatty acids and feedstock for biofuels. By utilizing power plant emissions and seawater, Seambiotic offers a sustainable approach to large-scale algae farming without competing for arable land or fresh water. Their business model encompasses technology licensing, research and development, and the commercialization of algae-derived supplements. The company gained international recognition for its pilot plant at the Ashkelon power station, which was the first to successfully grow algae using raw coal-fired flue gas.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Seambiotic.